L-Tryptophan
NootropicPreclinicalAlso known as: Tryptophan, L-Trp, Trp, (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid
L-Tryptophan is one of the nine essential amino acids — meaning the human body cannot synthesize it and must obtain it from dietary protein — and is the direct metabolic precursor to serotonin, melatonin, and (via a separate route) the vitamin niacin (nicotinamide / NAD+). It is the least abundant essential amino acid in most protein sources, and its selective depletion has been used for decades as a research tool to probe the role of serotonin in mood, cognition, and aggression.
Overview
At A Glance
L-Tryptophan acts primarily as the upstream precursor to serotonin, melatonin, and — via the dominant kynurenine pathway — NAD+ and a family of bioactive metabolites. Its pharmacology is metabolism-driven: tryptophan itself has no direct receptor binding of clinical significance;…
Mechanism of Action
L-Tryptophan acts primarily as the upstream precursor to serotonin, melatonin, and — via the dominant kynurenine pathway — NAD+ and a family of bioactive metabolites. Its pharmacology is metabolism-driven: tryptophan itself has no direct receptor binding of clinical significance; its effects derive from what the body does with it.
Serotonin pathway — the ~1-5% route that dominates clinical interest: Ingested tryptophan is absorbed in the small intestine via sodium-dependent neutral amino acid transporters (primarily B0AT1/SLC6A19 in the gut) and enters portal circulation. Peripheral tryptophan is partitioned between albumin-bound and free fractions. Free tryptophan crosses the blood-brain barrier via LAT1 (SLC7A5), a large neutral amino acid transporter that it shares — in direct competition — with leucine, isoleucine, valine, phenylalanine, tyrosine, and methionine. This LNAA competition is one of the single most important pharmacological facts about oral tryptophan. A high-protein meal raises blood tryptophan but raises competing LNAAs more, so the tryptophan:LNAA ratio at the BBB actually falls after a meat-rich meal. Conversely, a carbohydrate-only snack triggers insulin release that shunts branched-chain amino acids (leucine, isoleucine, valine) into skeletal muscle — lowering plasma LNAAs while leaving tryptophan relatively elevated — raising the tryptophan:LNAA ratio and delivering proportionally more tryptophan to brain. This is the mechanistic basis for the folk wisdom that carbs before bed aid sleep and for the conventional recommendation to take supplemental tryptophan with a small carbohydrate snack if sleep or mood effects are the goal.
TPH — the rate-limiting step: Inside serotonergic neurons, tryptophan is hydroxylated by tryptophan hydroxylase to 5-hydroxytryptophan (5-HTP). TPH exists in two isoforms: TPH1 (predominantly gut/periphery/pineal) and TPH2 (brain raphe nuclei). TPH is the rate-limiting enzyme of serotonin synthesis, is typically ~50% saturated at physiologic tryptophan levels, and requires tetrahydrobiopterin (BH4), iron (Fe2+), and molecular oxygen as cofactors. Under normal conditions, brain tryptophan concentration is sufficient to keep TPH partially saturated; raising plasma tryptophan modestly raises brain serotonin synthesis. Importantly, because TPH is rate-limiting and subject to end-product feedback regulation (high serotonin inhibits TPH), tryptophan's upward effect on serotonin is self-limiting — this is the mechanistic reason tryptophan is generally considered gentler and lower-risk than 5-HTP (which bypasses TPH entirely and converts directly via AADC to serotonin with no rate-limiting step). The cofactor requirements also explain why vitamin B6 (for the downstream AADC step), iron, and folate/B12 (for BH4 regeneration) are clinically relevant supporting nutrients — tryptophan conversion efficiency drops when cofactors are deficient.
AADC and serotonin: 5-HTP is decarboxylated by aromatic L-amino acid decarboxylase (AADC / DOPA decarboxylase) to serotonin (5-HT). AADC is a pyridoxal-5-phosphate (active B6) dependent enzyme and is not rate-limiting — 5-HTP is almost quantitatively converted to serotonin. AADC is also the enzyme that converts L-DOPA to dopamine, which is why large doses of tryptophan or 5-HTP can theoretically compete with dopamine synthesis (clinically minor in most contexts). Serotonin acts at a large family of 5-HT receptors (5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT6, 5-HT7 among others) in brain, gut, and vasculature.
Melatonin pathway: In the pineal gland, serotonin is acetylated by AA-NAT (arylalkylamine N-acetyltransferase) to N-acetylserotonin, then methylated by HIOMT/ASMT (hydroxyindole-O-methyltransferase) to melatonin. AA-NAT activity is circadian and darkness-dependent — this is why tryptophan's sleep effects are most pronounced when taken in the evening with dark/dim light exposure, and minimal when taken during the day under bright-light conditions. Raising endogenous melatonin via tryptophan is a slower, more physiologic route than taking exogenous melatonin, and is subject to circadian regulation rather than just dose-dependent.
Kynurenine pathway — the ~95% route: The vast majority of dietary tryptophan is metabolized through the kynurenine pathway, initiated by two enzymes: tryptophan 2,3-dioxygenase (TDO) in the liver (upregulated by glucocorticoids — stress shunts tryptophan into this pathway) and indoleamine 2,3-dioxygenase (IDO) in immune and peripheral tissues (upregulated by pro-inflammatory cytokines — interferon-gamma, TNF-alpha, IL-6). TDO and IDO both produce N-formylkynurenine, which is rapidly hydrolyzed to kynurenine. Kynurenine itself crosses the BBB and is further metabolized in brain along two competing branches:
- Neuroprotective arm — kynurenine aminotransferase (KAT) produces kynurenic acid (KYNA), a glycine-site NMDA receptor antagonist and α7-nicotinic acetylcholine receptor antagonist. Elevated KYNA has been associated with cognitive deficits but also with seizure protection and reduced excitotoxicity.
- Neurotoxic arm — kynurenine monooxygenase (KMO) → 3-hydroxykynurenine → quinolinic acid (QUIN), an NMDA receptor agonist and oxidative stressor. Elevated QUIN has been implicated in depression, HIV-associated neurocognitive disorder, Huntington's disease, and neuroinflammation.
The KMO vs KAT branch point in brain is influenced by inflammation (KMO is upregulated by inflammatory cytokines, shifting flux toward the neurotoxic arm) — this is one of the more active areas of contemporary depression and neuroinflammation research. Quinolinic acid ultimately feeds into NAD+ synthesis via quinolinate phosphoribosyltransferase (QPRT), the so-called "de novo NAD+ pathway" — humans make a small but physiologically relevant amount of niacin (as NAD+/NADP+) from dietary tryptophan, with a conversion ratio classically estimated at 60:1 (60mg tryptophan → 1mg niacin equivalent). This is why pellagra (niacin deficiency) is rare in high-protein diets even without direct niacin intake.
Niacin conversion: The tryptophan-to-NAD+ pathway is biologically meaningful: populations subsisting on corn-based diets (corn is particularly low in both tryptophan and bioavailable niacin) developed pellagra, the classic niacin-deficiency syndrome. Supplementing either tryptophan or niacin resolved the condition. For supplemental tryptophan users, the niacin side-effect contribution is modest at typical doses (1-3g) — flushing from niacin conversion is not usually a concern — but it is one reason tryptophan contributes to general nutritional status beyond just serotonin support.
Competitive transport and the carb-timing effect: As above, tryptophan's delivery to brain depends on the tryptophan:LNAA ratio at the BBB, not on absolute plasma tryptophan. Three practical consequences: (1) empty stomach, or with only a small carb snack, is the highest-yield timing for brain uptake; (2) taking tryptophan with a high-protein meal blunts its brain effect substantially (the meal's leucine/isoleucine/valine/phenylalanine/tyrosine flood the BBB transporter); (3) exercise — which lowers plasma BCAAs via muscle uptake — can also raise the tryptophan:LNAA ratio and is one proposed mechanism for exercise-related mood effects.
Why claims of dramatic mood effects warrant calibration: Tryptophan's mood effects are real but modest. Acute tryptophan depletion (ATD) experiments reliably reproduce depressive symptoms in people with a personal or family history of depression (Young 2013), supporting a causal role for serotonin availability in mood. However, supplementing tryptophan in clinical depression has produced mixed results — probably because the TPH rate-limit, kynurenine-pathway competition (particularly in inflammation-driven depression where IDO is upregulated), and serotonin-receptor-level pathology all mean that simply raising precursor availability is not sufficient to restore mood in established major depression. For self-experimenters with mild mood or sleep issues, tryptophan may produce a modest effect within 1-2 weeks; for clinical depression, it is not a substitute for evidence-based treatment.
Overview
L-Tryptophan is one of the nine essential amino acids — meaning the human body cannot synthesize it and must obtain it from dietary protein — and is the direct metabolic precursor to serotonin, melatonin, and (via a separate route) the vitamin niacin (nicotinamide / NAD+). It is the least abundant essential amino acid in most protein sources, and its selective depletion has been used for decades as a research tool to probe the role of serotonin in mood, cognition, and aggression. As a dietary supplement it sits at an unusual intersection: foundational nutrient, serotonin precursor, sleep aid, and the compound at the center of one of the most consequential supplement safety events in US regulatory history — the 1989 eosinophilia-myalgia syndrome (EMS) outbreak that killed roughly 37 people and sickened ~1,500, which was eventually traced to contaminants in a single manufacturer's bulk product (Showa Denko). That tragedy drove an FDA import alert and a near-total disappearance of tryptophan from the US supplement market for over a decade; it has since returned under USP-verified, third-party-tested sourcing, but the shadow of EMS continues to shape how cautious clinicians and regulators think about the compound.
Chemically, L-tryptophan is (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid — an aromatic amino acid defined by its indole ring, a bicyclic nitrogen-containing aromatic structure that is also the structural core of serotonin, melatonin, psilocin, DMT, and a wide family of indoleamine neuromodulators. The indole ring is what makes tryptophan fluorescent and what makes it the most spectroscopically distinctive amino acid in proteins. In dietary terms, it is abundant in turkey, chicken, eggs, cheese, fish, pumpkin seeds, soybeans, oats, and dairy — contrary to popular folklore, turkey is not unusually rich in tryptophan relative to other protein sources, and the post-Thanksgiving drowsiness attributed to turkey's tryptophan is more plausibly a function of carbohydrate-induced insulin release shunting competing large neutral amino acids into muscle, plus a large meal, plus alcohol, plus the parasympathetic lull of a long family dinner.
The supplemental rationale for L-tryptophan is tied almost entirely to its role as a precursor. Ingested tryptophan is absorbed in the small intestine, enters circulation, crosses the blood-brain barrier in competition with other large neutral amino acids (LNAAs) — leucine, isoleucine, valine, phenylalanine, tyrosine, methionine — and is converted in serotonergic neurons by tryptophan hydroxylase (TPH1 in the gut/periphery, TPH2 in the brain) to 5-hydroxytryptophan (5-HTP), which is then decarboxylated by AADC to serotonin (5-HT). Serotonin in the pineal gland is subsequently acetylated (by AA-NAT) and methylated (by HIOMT) to produce melatonin, the circadian-aligned sleep-promoting hormone. Only a small fraction of dietary tryptophan — typically cited as ~1-5% — follows this serotonin/melatonin path; the vast majority (~95%) is shunted through the kynurenine pathway via tryptophan 2,3-dioxygenase (TDO) in the liver or indoleamine 2,3-dioxygenase (IDO) in immune and peripheral tissues, generating kynurenine and a cascade of downstream metabolites (kynurenic acid, quinolinic acid, xanthurenic acid, picolinic acid) that feed into NAD+ synthesis and immune signaling. The kynurenine pathway is itself a topic of intense contemporary research — kynurenic acid is a glycine-site NMDA antagonist and α7-nicotinic antagonist (possibly neuroprotective), while quinolinic acid is an NMDA agonist and has been linked to depression, neuroinflammation, and neurodegeneration.
The historical context for tryptophan supplementation starts in the 1970s, when early sleep researchers — notably Ernest Hartmann at Boston State Hospital — reported that 1-4 grams of oral tryptophan reduced sleep latency in mild insomniacs without the "morning-after" grogginess associated with benzodiazepines. Through the 1980s, tryptophan was widely used for sleep, mood, and pre-menstrual symptoms across North America, sold as a dietary supplement in health food stores. In 1989, clusters of a new and frightening syndrome — severe eosinophilia, disabling myalgia, fasciitis, neuropathy — were reported from New Mexico and rapidly traced to L-tryptophan supplementation (Belongia et al. 1990, NEJM). Epidemiological investigation pinned the cases to bulk tryptophan manufactured by Showa Denko in Japan using a specific modified fermentation strain; contaminants (EBT, "peak E", plus related impurities) — not tryptophan itself — were the likely causative agents. FDA imposed an import alert; by 1990 tryptophan was effectively off US shelves. The import alert was relaxed in 2001-2005 as USP-verified sourcing and improved analytical methods allowed regulators to reintroduce the product; since then, L-tryptophan has been legally available in the US as a dietary supplement, but with ongoing emphasis on third-party testing and USP verification precisely because of the EMS legacy.
Current use is concentrated in three buckets: (1) sleep latency support — the original Hartmann-era indication; modest but real effect in mild insomnia (Silber & Schmitt 2010, review); (2) mood support — particularly in acute tryptophan depletion research (Young 2013) showing that depleting tryptophan rapidly reproduces low mood in people with a history of depression, supporting a causal role for serotonin availability; clinical response to supplemental tryptophan in actual depression is mixed; (3) niche applications — PMS symptoms, post-partum blues, aggression/irritability, carb-craving. Dosing is typically 500mg to 3g/day, often at bedtime or split. Onset for acute effects is ~30-90 minutes; steady-state serotonergic effects may take 1-2 weeks.
Who uses it and why — the practical picture — breaks down roughly as: people who want a gentler alternative to 5-HTP (tryptophan is upstream of the TPH rate-limit and therefore subject to homeostatic regulation that 5-HTP bypasses); people whose melatonin use has plateaued or who want endogenous melatonin support rather than exogenous dosing; people exploring serotonergic support without prescription SSRIs; and a smaller group using tryptophan as an aggression/irritability-reducing intervention (this has modest RCT support). If you're comparing this to 5-HTP, here's the tradeoff: tryptophan is the upstream amino acid subject to TPH regulation (harder to overshoot, gentler effect), while 5-HTP bypasses TPH and converts directly to serotonin (faster, more potent, but with more room to overshoot into serotonin syndrome territory when combined with serotonergic drugs). For most self-experimenters, tryptophan is the safer starting point.
See also 5-HTP, Melatonin, SAM-e, Magnesium, L-Theanine, Ashwagandha, Rhodiola, Lithium Orotate, and Lion's Mane for adjacent serotonergic, sleep-supportive, and mood-supportive compounds commonly used in the same stacks. This is educational content and not medical advice — tryptophan supplementation has real interactions with prescribed serotonergic medications (SSRIs, MAOIs, triptans, tramadol, dextromethorphan) and warrants physician-level guidance when those are in play.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications:
Known hypersensitivity to L-tryptophan, product excipients, or prior allergic reaction — discontinue if rash, swelling, or other allergic symptoms occur.
Concurrent MAOI use (phenelzine, tranylcypromine, selegiline, rasagiline, linezolid — an antibiotic with weak but clinically relevant MAOI activity, methylene blue — another accidental MAOI) — absolute contraindication. MAOIs prevent serotonin breakdown; adding tryptophan amplifies synthesis and substantially raises serotonin syndrome risk. This combination is among the most dangerous in psychiatry and must be avoided. Washout periods from MAOI discontinuation are typically 2 weeks before initiating tryptophan.
Concurrent SSRI, SNRI, or other serotonergic antidepressant use (sertraline, fluoxetine, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, etc.) — generally avoided due to serotonin syndrome risk. If switching from SSRI to tryptophan, allow at least 2 weeks washout for most SSRIs, 5-6 weeks for fluoxetine (due to its long half-life).
Carcinoid syndrome — a rare tumor-related condition in which neuroendocrine tumors produce excess serotonin. Tryptophan supplementation provides additional substrate for tumor serotonin synthesis and can exacerbate symptoms. Absolute contraindication.
Active pregnancy — tryptophan supplementation is not routinely recommended in pregnancy. Theoretical concerns about fetal serotonergic effects (serotonin signaling is important in fetal brain development and pharmacologic modulation during pregnancy is poorly characterized for tryptophan) argue for avoiding supplements and relying on dietary tryptophan from protein foods. Not an absolute contraindication in the sense of "unsafe at any dose," but strongly preferred to avoid.
Relative contraindications requiring medical guidance:
Severe hepatic dysfunction — TDO is the main hepatic tryptophan 2,3-dioxygenase; advanced liver disease can alter tryptophan metabolism and kynurenine-pathway flux. Not an absolute contraindication but warrants physician input and may warrant lower doses.
Severe renal impairment (eGFR <30) — kynurenine metabolites are partly renally cleared; accumulation of metabolites may occur with severely impaired clearance. Physician input is reasonable for long-term supplementation in advanced CKD.
Concurrent triptan use (sumatriptan, rizatriptan, eletriptan, almotriptan, naratriptan, frovatriptan, zolmitriptan — migraine abortive medications) — serotonergic activity overlaps; avoid routine daily tryptophan in users who take triptans frequently. Occasional triptan use with daily tryptophan requires awareness of serotonin syndrome risk, though reports of syndrome from this combination are rare.
Concurrent tramadol — tramadol has serotonergic activity (it is a weak SNRI in addition to being a weak mu-opioid agonist); concurrent daily tryptophan is generally avoided.
Concurrent high-dose dextromethorphan — DXM is serotonergic at high doses (as in recreational use or high-dose cough suppressant); concurrent tryptophan is a risk factor for serotonin syndrome.
Concurrent 5-HTP use — redundant (5-HTP is already one metabolic step downstream of tryptophan) and additive without mechanistic benefit. Avoid combining.
Concurrent St. John's wort — has SSRI-like serotonergic activity. Avoid combining.
Concurrent lithium — not directly serotonergic but associated with serotonin syndrome cases when combined with other serotonergic agents. Discuss with prescribing physician before combining therapeutic-dose lithium with supplemental tryptophan.
Concurrent MDMA or other serotonergic recreational drugs — absolute avoid. Serotonin syndrome risk is real and can be severe.
Bipolar disorder — tryptophan can theoretically destabilize mood in bipolar patients (any serotonergic agent has this theoretical risk). Not an absolute contraindication but warrants psychiatrist input and close monitoring for hypomanic/manic switching.
Current or recent eosinophilic illness — the 1989 EMS legacy means that any concurrent eosinophilic condition (eosinophilic esophagitis, Churg-Strauss syndrome, eosinophilic fasciitis) warrants avoiding tryptophan pending hematology/immunology workup.
Pregnancy-specific considerations: As above, not an absolute contraindication but strongly preferred to avoid supplementation during pregnancy. Dietary tryptophan from protein foods is fine and represents normal nutritional practice. If tryptophan is being considered during pregnancy for severe clinical indication, this is a physician-level decision.
Breastfeeding: Tryptophan is present in breast milk normally; supplemental dosing has limited specific safety data. Not recommended without obstetrician/pediatrician input.
Pediatric use: Not recommended under 18 years — insufficient safety and efficacy data for children and adolescents. Pediatric serotonergic supplementation, when clinically appropriate, is done with specialist guidance and typically uses alternative approaches.
Situations warranting medical consultation before use:
- Any psychiatric medication use — particularly SSRIs, SNRIs, MAOIs, lithium, buspirone, trazodone, mirtazapine.
- Migraine with triptan use — timing and frequency coordination.
- Chronic pain on tramadol — alternative non-serotonergic approaches preferred.
- Bipolar disorder — psychiatrist input.
- Pregnancy or planning pregnancy — default to dietary tryptophan.
- Severe liver or kidney disease — physician input on dose and appropriateness.
- Active eosinophilic or autoimmune illness — workup before supplementation.
- Surgery planned — generally no specific tryptophan concern with routine anesthesia, but inform surgical team of all supplements.
New neurological or autonomic symptoms on tryptophan — mental status changes, unusual tremor or clonus, autonomic signs (tachycardia, hyperthermia, diaphoresis), severe GI symptoms, muscle pain, or eosinophilia-like presentation warrant evaluation and discontinuation pending workup. Serotonin syndrome is the acute concern with concurrent serotonergic drug use; EMS-like reactions are historically rare with quality-sourced product but remain part of the legacy consideration.
Legal and regulatory status: L-Tryptophan is a dietary supplement in the US (since the early 2000s when the FDA import alert was relaxed following improvements in manufacturing and testing), Canada, UK, EU, Australia, and most countries — legally available without prescription. Not a controlled substance; not restricted in competitive sport (WADA permits amino acid supplementation). Products should comply with dietary supplement GMP and labeling requirements, and USP verification is strongly preferred given the EMS history.
Quality variability concern: As discussed in reconstitution notes, the 1989 EMS outbreak resulted from contaminants in a specific Showa Denko bulk product, not from tryptophan itself. Current USP-verified products are extensively tested and have an excellent safety record. Generic tryptophan from unverified overseas bulk sources carries real (if small) quality-variance risk. Prefer USP-verified product for any chronic or higher-dose use.
Not medical advice: This content is educational. Specific use decisions — particularly in psychiatric medication contexts, pregnancy, liver or kidney disease, or with any serotonergic drug interaction — warrant physician-level guidance tailored to individual circumstances. Research compound — not a substitute for evidence-based medical care.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for L-Tryptophan.
Related Compounds
View AllAlpha-GPC
NootropicPhase 4Alpha-GPC (chemical name L-alpha-glycerylphosphorylcholine; pharmaceutical name choline alfoscerate) is a naturally occurring cholinergic compound that serves as a highly bioavailable precursor to both acetylcholine (the primary neurotransmitter of the cholinergic system, central to learning, memory, attention, and neuromuscular function) and phosphatidylcholine (the principal phospholipid building block of neuronal cell membranes).
Caffeine
NootropicPreclinicalCaffeine (1,3,7-trimethylxanthine) is a natural methylxanthine alkaloid found in the seeds, fruits, leaves, and bark of over 60 plant species — most notably Coffea (coffee), Camellia sinensis (tea), Theobroma cacao (cacao), Paullinia cupana (guaraná), Ilex paraguariensis (yerba mate), and Cola acuminata (kola nut).
CDP-Choline
NootropicPhase 4CDP-choline (cytidine 5'-diphosphocholine, pharmaceutical name citicoline) is a naturally occurring intracellular intermediate in the Kennedy pathway for phosphatidylcholine synthesis — the primary biochemical route by which all nucleated cells produce the dominant membrane phospholipid.
Inositol
NootropicPreclinicalInositol is a naturally-occurring cyclic sugar alcohol (cyclohexanehexol) that functions as a critical structural component of cell membranes and a second-messenger precursor in intracellular signaling.
Magnesium L-Threonate
NootropicPreclinicalMagnesium L-Threonate is a proprietary chelated form of magnesium in which the magnesium cation is bound to L-threonic acid — a metabolite of ascorbic acid (vitamin C) — forming the salt commonly marketed under the brand name Magtein.
VIP
NootropicPreclinicalVIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide and hormone that is widely expressed throughout the central and peripheral nervous systems, gastrointestinal tract, and immune system.
View Full Dosage Guide →
Protocols, calculator & safety for L-Tryptophan
Research Score
80432 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Well-researched compound
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
L-Tryptophan vs 5-HTP — which should I choose?
Both eventually produce serotonin, but they differ meaningfully. L-Tryptophan is the upstream amino acid and is converted to 5-HTP by tryptophan hydroxylase (TPH), which is the rate-limiting enzyme of serotonin synthesis. TPH is subject to end-product feedback regulation, so tryptophan's effect on serotonin is gentler, more physiologic, and harder to overshoot. 5-HTP bypasses TPH entirely — it's one step downstream and converts almost quantitatively to serotonin via AADC. Result: 5-HTP is faster-acting, more potent per mg, but with more room to overshoot (slightly higher serotonin syndrome risk with interacting drugs) and less subject to homeostatic feedback. Practical rule: start with L-tryptophan 500mg-1g at bedtime for 2-4 weeks. If no effect at 1-2g/day, consider switching to 5-HTP 50-100mg — this bypasses the TPH rate-limit that may be preventing response. Don't combine tryptophan and 5-HTP (redundant, additive, no mechanistic benefit). For most first-time self-experimenters, tryptophan is the safer starting point; 5-HTP is the tighter-dose alternative if tryptophan underperforms.
Does L-Tryptophan actually help sleep?
Yes, but the effect is modest. Silber & Schmitt 2010 (PMID: 19887142) — the modern sleep review pooling decades of tryptophan research — concluded that oral tryptophan 1-4g at bedtime modestly reduces sleep latency in mild insomniacs, with smaller effects on sleep architecture and minimal next-day impairment. Effect size is roughly 10-15 minutes reduction in time to sleep onset. For severe or chronic insomnia, tryptophan alone is usually insufficient — CBT-I (cognitive behavioral therapy for insomnia) is first-line for chronic cases, and prescription sleep aids remain relevant for severe cases. Tryptophan is a reasonable choice for mild sleep-onset difficulty where you want a gentle, non-habit-forming option. Take 500mg-1g 30-60 minutes before bedtime with a small carbohydrate snack (mechanistically important — raises brain tryptophan uptake via insulin-driven BCAA muscle uptake). Expect modest improvement in sleep onset within 3-7 days; honest assessment at 2 weeks is appropriate. Don't expect tryptophan to overcome poor sleep hygiene, excessive caffeine, screen exposure, or underlying sleep disorders (sleep apnea, restless legs).
Is the 1989 EMS danger still real?
The short answer: contamination-caused EMS is extremely rare with current USP-verified product, but the history genuinely changed how regulators and careful clinicians think about tryptophan sourcing. Background: In 1989, clusters of a new and serious syndrome — severe eosinophilia, disabling myalgia, fasciitis, neuropathy — were reported and rapidly traced to L-tryptophan supplementation. Belongia et al. 1990 (NEJM PMID: 2370676) pinned the cases (~1,500 reported, ~37 deaths) to bulk tryptophan manufactured by Showa Denko in Japan using a modified fermentation strain. Specific contaminants ('peak E' / EBT / 1,1'-ethylidenebis[tryptophan], plus related impurities) — not tryptophan itself — were the likely causative agents. FDA imposed an import alert; tryptophan effectively disappeared from US shelves for over a decade. The alert was relaxed in ~2001-2005 as USP-verified sourcing and improved analytical methods made contamination detection routine. Current reality: USP-verified, GMP-manufactured, third-party-tested L-tryptophan — the kind sold by Pure Encapsulations, NOW Foods, Thorne, Life Extension, Ajinomoto-sourced products — has an excellent safety record for over 20 years now. The risk is real but small, and is entirely a sourcing question: generic tryptophan from unverified overseas bulk at suspiciously low prices carries meaningful risk; USP-verified product from established brands does not. Pay the extra $10-15/month for USP-verified; it is genuinely worth it.
Can I take L-Tryptophan with my SSRI?
Generally no, without explicit physician guidance. SSRIs (sertraline, fluoxetine, paroxetine, citalopram, escitalopram) and tryptophan both raise serotonin availability, and the combination carries real serotonin syndrome risk — a potentially life-threatening state characterized by mental status changes, autonomic hyperactivity, and neuromuscular hyperactivity. The risk is not theoretical; case reports exist. If switching from SSRI to tryptophan, allow at least 2 weeks washout for most SSRIs, 5-6 weeks for fluoxetine (due to its long half-life). If currently on SSRI and considering adding tryptophan for mood support — discuss with prescribing psychiatrist first. Some psychiatrists may approve low-dose tryptophan (500mg) as an adjunct in specific circumstances with close monitoring; this is not standard practice and should not be attempted without explicit medical guidance. Symptoms of serotonin syndrome are typically acute (hours to a day after starting the combination or escalating dose) and warrant emergency evaluation. Same guidance applies to SNRIs, MAOIs, triptans (frequent use), tramadol, high-dose dextromethorphan, St. John's wort, and lithium. Review all medications for serotonergic activity before starting tryptophan.
What's the best time to take L-Tryptophan?
Most commonly evening, 30-60 minutes before bedtime, with a small carbohydrate snack. The rationale is twofold. First, tryptophan's downstream serotonin → N-acetylserotonin → melatonin pathway produces mild sedation and supports sleep onset — evening timing captures this. Second, a small carb snack (~20-30g carbs, minimal protein — half a banana, a slice of whole-grain toast, a small bowl of rice) is mechanistically important: insulin-driven BCAA muscle uptake raises the tryptophan:LNAA ratio at the blood-brain barrier and delivers proportionally more tryptophan to brain. Taking tryptophan with a high-protein meal blunts its brain effect because competing large neutral amino acids (leucine, isoleucine, valine, phenylalanine, tyrosine, methionine) saturate the LAT1 transporter. For mood-only use, split AM/PM dosing is also reasonable (Lindseth 2015 style), but most users find the evening dose alone sufficient. AM dosing can cause daytime drowsiness in sensitive users; test individually before relying on it for daytime activities. Consistent daily dosing is better than sporadic use for mood effects; for sleep, use as-needed dosing is also reasonable. Fernstrom 2013 (PMID: 23077193) reviews the LNAA-competition framework in detail.
What dose should I take for depression?
Honest answer: tryptophan is not a first-line antidepressant, and no dose will reliably treat established major depression. Evidence: Acute tryptophan depletion (Young 2013, PMID: 22889546) reliably reproduces depressive symptoms in people with a history of depression — supporting a causal role for serotonin availability. But raising tryptophan in established MDD has produced mixed and largely negative RCT results. Probable reasons: the TPH rate-limit, kynurenine-pathway competition (particularly in inflammation-driven depression where IDO shunts tryptophan away from serotonin), and receptor-level pathology all mean that simply raising precursor availability isn't sufficient in established depression. What tryptophan can do: modest support for mild low mood in healthy or minimally-depressed adults (Lindseth 2015, PMID: 25858202 — 1-2g/day improved mood scores in healthy young adults). Reasonable role: mild mood dip or stress-related low mood at 1-2g/day split AM/PM, with cofactor support (B6, magnesium, methylfolate, methylcobalamin, omega-3, vitamin D). Not a reasonable role: treating clinical depression in lieu of SSRIs or evidence-based treatment. If you have persistent low mood interfering with function, see a physician or psychiatrist — tryptophan may be an adjunct in some plans but is not a substitute for evidence-based care.
Does turkey really make you sleepy?
Not really — or at least, not for the reason folklore suggests. Turkey is not unusually rich in tryptophan relative to other common protein sources. Per gram of protein, turkey has roughly the same tryptophan content as chicken, cheese, eggs, fish, and soybeans. The post-Thanksgiving drowsiness is more plausibly explained by: (1) a large meal (large meals of any composition produce some postprandial drowsiness via parasympathetic activation and redistribution of blood flow to gut); (2) high carbohydrate intake (mashed potatoes, stuffing, pie) which raises insulin and shunts BCAAs into muscle — paradoxically, this does raise the tryptophan:LNAA ratio slightly, but from the baseline tryptophan in the meal, not from anything special about turkey; (3) alcohol (wine, beer) which has its own sedative effects; (4) the parasympathetic lull of a long, warm, social meal with family — a setting that would produce drowsiness regardless of protein source. So: the tryptophan explanation for Thanksgiving sleepiness is a myth of biochemistry. That said, the mechanism it points to — that dietary tryptophan combined with insulin-driven BCAA muscle uptake does affect brain tryptophan delivery — is real, and is the basis for why carb-timing matters for supplemental tryptophan dosing (Fernstrom 2013).
Is the kynurenine pathway good or bad?
It's both — it depends on which branch and which context. The kynurenine pathway handles ~95% of dietary tryptophan (only ~1-5% goes to serotonin/melatonin). Tryptophan 2,3-dioxygenase (TDO, liver) and indoleamine 2,3-dioxygenase (IDO, immune and peripheral tissues) initiate the pathway, producing kynurenine. Kynurenine then branches in brain along two competing arms: Neuroprotective arm — kynurenine aminotransferase (KAT) produces kynurenic acid (KYNA), a glycine-site NMDA antagonist and α7-nicotinic antagonist. High KYNA has been associated with cognitive deficits but also with seizure protection and reduced excitotoxicity. Neurotoxic arm — kynurenine monooxygenase (KMO) → 3-hydroxykynurenine → quinolinic acid (QUIN), an NMDA agonist and oxidative stressor. Elevated QUIN has been implicated in depression, neuroinflammation, HIV-associated cognitive impairment, and neurodegeneration. The branch point is inflammation-sensitive: inflammatory cytokines (interferon-gamma, TNF, IL-6) upregulate both IDO (pulling tryptophan into the pathway) and KMO (shunting toward the neurotoxic quinolinic acid arm). This is one mechanism linking chronic inflammation to depression and cognitive symptoms, and KMO inhibitors are being investigated as novel antidepressants. Quinolinic acid also ultimately feeds NAD+ synthesis (60:1 conversion ratio — 60mg tryptophan → 1mg niacin equivalent), so the pathway isn't purely harmful — it's how humans make a small but meaningful fraction of their niacin. Practical upshot for supplemental tryptophan users: most dietary and supplemental tryptophan goes through the kynurenine pathway normally; the pathway becomes a concern in chronic inflammatory states, where anti-inflammatory interventions (omega-3, exercise, sleep, underlying condition management) matter more than tryptophan dose.
What brands of L-Tryptophan can I trust?
Given the 1989 EMS legacy, sourcing is genuinely important for tryptophan. The short list of established brands with USP verification, GMP manufacturing, and third-party testing: Pure Encapsulations (L-Tryptophan capsules), NOW Foods (with independent testing), Thorne Research, Life Extension, Jarrow Formulas, Double Wood Supplements, Designs for Health. Also reputable: anything explicitly Ajinomoto-sourced — Ajinomoto is a large, well-regulated Japanese amino acid manufacturer with a strong reputation for purity and is widely considered the gold standard for supplemental amino acid sourcing. What to look for on the label: (1) 'USP Verified' mark; (2) 'GMP manufactured'; (3) explicit third-party testing statement with published COAs on the manufacturer website; (4) Ajinomoto-sourced if specified; (5) simple, clean formulation without unusual additives. What to avoid: generic 'tryptophan' from unverified overseas bulk sources at suspiciously low prices; 'proprietary blends' that don't specify L-tryptophan content; products without clear third-party testing or USP verification. Typical USP-verified tryptophan costs $15-30/month at 1-2g/day dosing — pay it. Bulk Ajinomoto-sourced powder is more cost-effective for chronic higher-dose use ($10-20/month equivalent) from reputable bulk suppliers. The EMS history is not ancient — quality sourcing is not optional.
Is L-Tryptophan safe during pregnancy?
Supplemental L-tryptophan is not routinely recommended during pregnancy, and most obstetricians would advise defaulting to dietary tryptophan (from protein foods — turkey, chicken, eggs, dairy, fish, soybeans) rather than supplements. Reasons for caution: (1) Serotonin signaling is important in fetal brain development, and pharmacologic modulation during pregnancy is poorly characterized for tryptophan specifically; (2) tryptophan supplementation during pregnancy has not been systematically studied for maternal or fetal safety outcomes; (3) there are better-studied alternatives for the common indications — magnesium for sleep and mild anxiety, CBT-I for insomnia, physician-guided management for mood concerns. It is not an 'absolute contraindication' in the sense of 'unsafe at any dose' — dietary tryptophan from food is obviously fine and represents normal nutrition — but supplementation during pregnancy is a discussion to have with your obstetrician, not a decision to make based on general supplement literature. Breastfeeding: similar considerations — tryptophan is present in breast milk normally, but supplemental dosing has limited specific safety data. Discuss with obstetrician/pediatrician. For mood or sleep issues during pregnancy or breastfeeding, first-line approaches are non-pharmacologic (CBT-I for insomnia, CBT or interpersonal therapy for mood) and physician-guided if medication becomes necessary. Research compound — not medical advice, and particularly not medical advice for pregnancy.
Research Tools
Related Compounds
View AllAlpha-GPC
NootropicPhase 4Alpha-GPC (chemical name L-alpha-glycerylphosphorylcholine; pharmaceutical name choline alfoscerate) is a naturally occurring cholinergic compound that serves as a highly bioavailable precursor to both acetylcholine (the primary neurotransmitter of the cholinergic system, central to learning, memory, attention, and neuromuscular function) and phosphatidylcholine (the principal phospholipid building block of neuronal cell membranes).
Caffeine
NootropicPreclinicalCaffeine (1,3,7-trimethylxanthine) is a natural methylxanthine alkaloid found in the seeds, fruits, leaves, and bark of over 60 plant species — most notably Coffea (coffee), Camellia sinensis (tea), Theobroma cacao (cacao), Paullinia cupana (guaraná), Ilex paraguariensis (yerba mate), and Cola acuminata (kola nut).
CDP-Choline
NootropicPhase 4CDP-choline (cytidine 5'-diphosphocholine, pharmaceutical name citicoline) is a naturally occurring intracellular intermediate in the Kennedy pathway for phosphatidylcholine synthesis — the primary biochemical route by which all nucleated cells produce the dominant membrane phospholipid.
Inositol
NootropicPreclinicalInositol is a naturally-occurring cyclic sugar alcohol (cyclohexanehexol) that functions as a critical structural component of cell membranes and a second-messenger precursor in intracellular signaling.
Magnesium L-Threonate
NootropicPreclinicalMagnesium L-Threonate is a proprietary chelated form of magnesium in which the magnesium cation is bound to L-threonic acid — a metabolite of ascorbic acid (vitamin C) — forming the salt commonly marketed under the brand name Magtein.
VIP
NootropicPreclinicalVIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide and hormone that is widely expressed throughout the central and peripheral nervous systems, gastrointestinal tract, and immune system.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
